Title : Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma.

Pub. Date : 2022 Jun

PMID : 35037771






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) used for the treatment of non-small cell lung cancer (NSCLC) presenting an EGFR mutation. osimertinib epidermal growth factor receptor Homo sapiens
2 INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) used for the treatment of non-small cell lung cancer (NSCLC) presenting an EGFR mutation. osimertinib epidermal growth factor receptor Homo sapiens
3 INTRODUCTION: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) used for the treatment of non-small cell lung cancer (NSCLC) presenting an EGFR mutation. osimertinib epidermal growth factor receptor Homo sapiens
4 Although Osimertinib has a better safety profile compared to older EGFR-TKIs and although adverse events (AEs) are described in literature, recently the relationship between Osimertinib therapy and cardiotoxicity is gaining attention. osimertinib epidermal growth factor receptor Homo sapiens